Some aspects of supportive care and diagnosis in the course of fulwestrant hormonotherapy of disseminated breast cancer

Abstract

Breast cancer is the most common women neoplasm. Despite standard primary treatment, there are quite a lot cases who progress. So appropriate anticancer systemic therapy is necessary. Nowadays there can be used chemotherapy, hormonotherapy and immunotherapy. A case report of a female patient is presented, who progressed after six years of primary treatment. In spite of missing data of the estrogen and progesterone receptors status in the primary tumor, second and third line of hormonotherapy was introduced. Additionally local radiotherapy, oral and intravenous bisphosphonates, and strontium treatment were applied. 21 years of overall survival was accomplished and now during Fulvestrant treatment the patient is in remission. This case is the example of high efficacy of several lines of hormonotherapy in a estrogen-sensitive patient without need for chemotherapy.